Cargando…

Cerebrospinal fluid neurogranin as a new player in prion disease diagnosis and prognosis

Detalles Bibliográficos
Autores principales:	Villar-Piqué, Anna, Zerr, Inga, Llorens, Franc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990787/ https://www.ncbi.nlm.nih.gov/pubmed/31719249 http://dx.doi.org/10.4103/1673-5374.268901

Ejemplares similares

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients
por: Zerr, Inga, et al.
Publicado: (2019)

Optimization of the Real-Time Quaking-Induced Conversion Assay for Prion Disease Diagnosis
por: Zerr, Inga, et al.
Publicado: (2020)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies
por: Canaslan, Sezgi, et al.
Publicado: (2021)

Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
por: Schmitz, Matthias, et al.
Publicado: (2022)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
por: Llorens, Franc, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer’s disease
por: Xue, Mei, et al.
Publicado: (2020)

MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives
por: Kanata, Eirini, et al.
Publicado: (2018)

Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients
por: Schmitz, Matthias, et al.
Publicado: (2016)

Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease
por: Podlesniy, Petar, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia
por: Llorens, Franc, et al.
Publicado: (2017)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology
por: Portelius, Erik, et al.
Publicado: (2018)

TREM2 expression in the brain and biological fluids in prion diseases
por: Diaz-Lucena, Daniela, et al.
Publicado: (2021)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
por: Becker, Bruno, et al.
Publicado: (2018)

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease
por: Llorens, Franc, et al.
Publicado: (2020)

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease
por: De Vos, Ann, et al.
Publicado: (2016)

Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
por: Liu, Weilin, et al.
Publicado: (2020)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease
por: Zerr, Inga, et al.
Publicado: (2021)

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease
por: Kivisäkk, Pia, et al.
Publicado: (2022)

Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers
por: Hermann, Peter, et al.
Publicado: (2022)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

The role of cellular prion protein in lipid metabolism in the liver
por: Arora, Amandeep Singh, et al.
Publicado: (2020)

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease
por: Herden, Janne Marieke, et al.
Publicado: (2023)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2018)

YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
por: Andrés-Benito, Pol, et al.
Publicado: (2018)

Correction: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non‑rapidly progressive Alzheimer’s disease
por: Herden, Janne Marieke, et al.
Publicado: (2023)

Human prion diseases: progress in clinical trials
por: Zerr, Inga
Publicado: (2013)

Correction for: YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
por: Andrés‐Benito, Pol, et al.
Publicado: (2021)

Prion2022-pushing the boundaries
por: Zerr, Inga
Publicado: (2023)

Progress in CSF biomarker discovery in sCJD
por: Llorens, Franc, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o27n0lhmlik2ua7kkq7ao29ff4